Hernandez Edgardo
Known title: EVP & Pres., Mfg. OperationsCIK: 0001861052
Associated companies
Transaction History
| LLY | ▼ Sell | Gift | 13 | $0 | 9/2/2026 | View on chart |
| LLY | ▲ Buy | Grant | 4,384 | $4.6M | 2/9/2026 | View on chart |
| LLY | ▲ Buy | Option Exercise | 3,572 | $0 | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,591 | $1.7M | 2/1/2026 | View on chart |
| LLY | ▼ Sell | Gift | 17 | $0 | 9/5/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,260 | $1.2M | 3/1/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 2,837 | $0 | 3/1/2025 | View on chart |
| LLY | ▲ Buy | Grant | 5,974 | $5.2M | 2/10/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 2,861 | $0 | 2/1/2025 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 1,282 | $1.0M | 2/1/2025 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,687 | $0 | 11/1/2024 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 751 | $615K | 11/1/2024 | View on chart |
| LLY | ▲ Buy | Grant | 2,821 | $2.1M | 2/12/2024 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,890 | $0 | 3/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 843 | $262K | 3/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 5,204 | $1.8M | 2/10/2023 | View on chart |
| LLY | ▲ Buy | Grant | 5,435 | $1.3M | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.